Back to first-pass browser

First-pass extracted concept

Drotrecogin alfa (activated)

Candidate: toolkit item1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

recombinant human activated protein C

Extracted Explainers

What the tool is doing

Drotrecogin alfa (activated) is a recombinant human activated protein C intervention evaluated for severe sepsis. The abstract states that it has antithrombotic, antiinflammatory, and profibrinolytic properties.

Source 1DOIPubMed

Resources required

The trial used an intravenous infusion at 24 microg per kilogram per hour for a total of 96 hours. Use was studied in patients with systemic inflammation and organ failure due to acute infection.

Source 1DOIPubMed

What problem it solves

The paper evaluates whether this treatment reduces death from any cause in severe sepsis, and reports lower mortality than placebo at 28 days.

Source 1DOIPubMed

What it does not solve

The abstract indicates a possible increase in serious bleeding risk, so the treatment does not avoid major safety tradeoffs.

Source 1DOIPubMed

Alternatives

The trial directly compares drotrecogin alfa (activated) with placebo.

Source 1DOIPubMed

Evidence Snippets

Drotrecogin alfa (activated), or recombinant human activated protein C
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1mechanistic rationalesupports2001Source 1DOIPubMed

Drotrecogin alfa (activated) has antithrombotic, antiinflammatory, and profibrinolytic properties.

Claim 2safety signalsupports2001Source 1DOIPubMed

Drotrecogin alfa (activated) was associated with a higher incidence of serious bleeding than placebo in patients with severe sepsis.

Claim 3therapeutic efficacysupports2001Source 1DOIPubMed

Drotrecogin alfa (activated) reduced 28-day all-cause mortality compared with placebo in patients with severe sepsis in this phase 3 randomized trial.